Industry Briefs: Mar. 5, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Galapagos has received EUR 3.5 million ($4.59 million) in milestone payments in its osteoarthritis alliance with Servier. Read More
JHP Pharmaceuticals has added a second product to its previously announced multiyear contract manufacturing agreement with an undisclosed pharmaceutical company. JHP will be responsible for manufacturing and supply of an injectable anesthetic agent. Read More
Lonza and Eclipse Therapeutics have formed a development and manufacturing agreement. Read More
Mylan continues to pursue damages and and its injunction against Sunovion’s Brovana in an ongoing litigation. Mylan believes a federal district court erred in its partial summary judgment decision. Read More
Pfenex and DNA2.0 have formed a collaboration on protein expression technology. Read More
People News
Albany Molecular Research (AMRI) has named Tom McGrath as director of quality for aseptic services, and Chris Phillips has been appointed to the role of senior director of operations, at AMRI’s Burlington, Massachusetts site. Read More
Alkermes has appointed Mark Stejbach as chief commercial officer. Read More
AstraZeneca has announced the retirement of Louis Schweitzer from the board as chairman and as a director, effective Sept. 1, 2012. Read More
Novartis has named Brian McNamara division head of Novartis OTC. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
